These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2868491)

  • 21. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity.
    Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A
    Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceruletide for schizophrenia: a double-blind study.
    Mattes JA; Hom W; Rochford JM; Orlosky M
    Biol Psychiatry; 1985 May; 20(5):533-8. PubMed ID: 2859054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for coexistence of dopamine and CCK in meso-limbic neurones.
    Hökfelt T; Rehfeld JF; Skirboll L; Ivemark B; Goldstein M; Markey K
    Nature; 1980 Jun; 285(5765):476-8. PubMed ID: 6105617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and neuroendocrine studies with cholecystokinin peptides.
    Nair NP; Bloom D; Lal S; Debonnel G; Schwartz G; Mosticyan S
    Ann N Y Acad Sci; 1985; 448():535-41. PubMed ID: 2862831
    [No Abstract]   [Full Text] [Related]  

  • 25. Subcortical limbic 3H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro.
    Agnati LF; Fuxe K
    Biosci Rep; 1983 Dec; 3(12):1101-5. PubMed ID: 6320923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor.
    Martin JR; Beinfeld MC; Wang RY
    Brain Res; 1986 Nov; 397(2):253-8. PubMed ID: 2948613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine receptors, neuroleptics, and schizophrenia.
    Snyder SH
    Am J Psychiatry; 1981 Apr; 138(4):460-4. PubMed ID: 6111227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.
    Van Ree JM; Gaffori O; De Wied D
    Eur J Pharmacol; 1983 Sep; 93(1-2):63-78. PubMed ID: 6138272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.
    Ballaz SJ; Bourin M
    Curr Neuropharmacol; 2021; 19(7):925-938. PubMed ID: 33185164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Release of cholecystokinin in the central nervous system.
    Raiteri M; Paudice P; Vallebuona F
    Neurochem Int; 1993 Jun; 22(6):519-27. PubMed ID: 8513278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8).
    Murphy RB; Schuster DI
    Peptides; 1982; 3(3):539-43. PubMed ID: 6289286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study.
    Nair NP; Bloom DM; Debonnel G; Schwartz G; Mosticyan S
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):711-4. PubMed ID: 6152344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY; Hu XT
    Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
    Innis RB; Bunney BS; Charney DS; Price LH; Glazer WM; Sternberg DE; Rubin AL; Heninger GR
    Psychiatry Res; 1986 May; 18(1):1-7. PubMed ID: 3737785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholecystokinin receptor subtypes and neuromodulation.
    Altar CA
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):381-93. PubMed ID: 2748871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of dopamine D2 receptor affinity by cholecystokinin octapeptide in fibroblast cells cotransfected with human CCKB and D2L receptor cDNAs.
    Dasgupta S; Li XM; Jansson A; Finnman UB; Matsui T; Rinken A; Arenas E; Agnati LF; Fuxe K
    Brain Res Mol Brain Res; 1996 Mar; 36(2):292-9. PubMed ID: 8965650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
    Peselow E; Angrist B; Sudilovsky A; Corwin J; Siekierski J; Trent F; Rotrosen J
    Psychopharmacology (Berl); 1987; 91(1):80-4. PubMed ID: 2881320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic regulation of cholecystokinin mRNA content in rat striatum.
    Ding XZ; Mocchetti I
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):77-83. PubMed ID: 1312208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission.
    Hurd YL; Lindefors N; Brodin E; Brené S; Persson H; Ungerstedt U; Hökfelt T
    Brain Res; 1992 Apr; 578(1-2):317-26. PubMed ID: 1354999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.